Icosavax to Participate in the Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical firm, announced its participation in the Cowen 42nd Annual Health Care Conference, scheduled for March 7-9, 2022. Adam Simpson, CEO, will join an Infectious Disease corporate panel on March 9 at 10:30 a.m. Eastern Time. Interested parties can access the live audio webcast via the Investor Relations section of the Icosavax website, with replays available for 30 days post-event.

The company focuses on innovative virus-like particle technology for vaccine development against respiratory diseases, including candidates targeting RSV, hMPV, and SARS-CoV-2.

SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced that the company will participate in the Cowen 42^nd Annual Health Care Conference taking place virtually from March 7-9, 2022.

Adam Simpson, Chief Executive Officer of Icosavax, is scheduled to participate in the Infectious Disease corporate panel discussion on Wednesday, March 9, at 10:30 a.m. Eastern Time.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.icosavax.com. The webcast replay will be available after the conclusion of the panel discussion for approximately 30 days.

About Icosavax

Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and an emerging program in influenza. Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle.

Media Contact: 
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
+1.858.344.8091

Investor Contact: 
Laurence Watts
Gilmartin Group, LLC
laurence@gilmartinir.com
+1.619.916.7620

FAQ

What is Icosavax's participation in the Cowen 42nd Annual Health Care Conference?

Icosavax will participate in the Cowen 42nd Annual Health Care Conference from March 7-9, 2022, with CEO Adam Simpson speaking on March 9 at 10:30 a.m. Eastern Time.

How can I access the Icosavax conference webcast?

The live audio webcast for the conference can be accessed from the Investor Relations section of Icosavax's website.

What vaccine technologies does Icosavax utilize?

Icosavax uses innovative virus-like particle (VLP) technology to develop vaccines against infectious diseases, focusing initially on life-threatening respiratory diseases.

What are the key vaccine candidates in Icosavax's pipeline?

Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2.

When will the webcast replay of the Icosavax conference be available?

The webcast replay will be available for approximately 30 days after the conclusion of the panel discussion on March 9, 2022.